☆ 4.2 Article

Graft versus Leukemia Reactivity after Allogeneic Stem Cell Transplantation

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Volume 17, Issue 1, Pages S33-S38

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.bbmt.2010.11.009

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Mesenchymal stem cell-derived exosomes can alleviate GVHD and preserve the GVL effect in allogeneic stem cell transplantation animal models

Yan Jiang, Jie Zhao, Minghui Wang, Fang Huang, Jiaqi Li, Rui Liu, Jiangbo Wan, Siguo Hao

Summary: This study demonstrates that MEXs exert their effects by inhibiting the immunomodulatory function of DCs, macrophages, and T lymphocytes, aiding in alleviating GVHD symptoms and preserving the antitumor effects of CD8+ T lymphocytes.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Pancreatic atrophy and recovery after allogeneic hematopoietic cell transplantation

Yosuke Okada, Hideki Nakasone, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shimpei Matsumi, Ayumi Gomyo, Aki Tanihara, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Shun-Ichi Kimura, Shinichi Kako, Noriko Oyama-Manabe, Yoshinobu Kanda

Summary: Pancreatic atrophy is associated with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. The recovery of pancreatic thickness plays a crucial role in body weight recovery, but pancreatic atrophy may have a negative impact on prognosis.

JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome

Georg-Nikolaus Franke, Konstantin Dumann, Madlen Jentzsch, Astrid Monecke, Christine Doehring, Claudia Nehring-Vucinic, Sebastian Schwind, Dietger Niederwieser, Uwe Platzbecker, Mirjana Ziemer, Vladan Vucinic

Summary: This case demonstrates that alloHSCT can be a curative option for refractory SS patients. Achieving complete remission after tapering immunosuppressive therapy indicates the significant role of the GvL effect. The timing of alloHSCT and the intensity of conditioning should be further explored in current treatment algorithms for SS patients.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease

Michael Stadler, Lothar Hambach, Elke Dammann, Helmut Diedrich, Haytham Kamal, Iyas Hamwi, Christian Schultze-Florey, Michael Varvenne, Steve Ehrlich, Stefanie Buchholz, Christian Koenecke, Gernot Beutel, Eva M. Weissinger, Juergen Krauter, Matthias Eder, Bernd Hertenstein, Arnold Ganser

Summary: Prophylactic donor lymphocyte infusions (proDLI) can prevent leukemia relapse after alloSCT. This study found that proDLI applied beyond day +120 post alloSCT can improve overall survival, disease-free survival, and reduce relapse incidence and non-relapse mortality in high-risk AL or MDS patients.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Review Oncology

Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Desiree Kunadt, Friedrich Stoelzel

Summary: The number of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has been increasing due to advances in transplant technology, supportive care, transplant safety, and donor availability. Acute myeloid leukemia (AML) is the most common indication for alloHCT, but disease relapse remains a major challenge. Maintaining a strong graft-versus-leukemia (GvL) effect is crucial for patient prognosis and long-term survival.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection

Review Oncology

Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation

Dionysios Vythoulkas, Panagiotis Tsirigotis, Marianna Griniezaki, Ioannis Konstantellos, Ioanna Lazana

Summary: Hematopoietic stem cell transplantation is associated with endothelial dysfunction and the expression of multiple substances, leading to a procoagulant and proinflammatory state. Early diagnosis of endothelial dysfunction syndromes is crucial, but there is currently a lack of ideal biomarkers. Further research is needed to identify novel biomarkers with sufficient specificity and sensitivity.

CANCERS (2023)

Add to Collection

Article Immunology

Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease

Thomas Krueger, Rebekka Wehner, Maik Herbig, Martin Kraeter, Michael Kramer, Jan Moritz Middeke, Friedrich Stoelzel, Catrin List, Katharina Egger-Heidrich, Raphael Teipel, Uta Oelschlaegel, Martin Wermke, Helena Jambor, Manja Wobus, Johannes Schetelig, Korinna Joehrens, Torsten Tonn, Julien Subburayalu, Marc Schmitz, Martin Bornhauser, Malte von Bonin

Summary: Functional impairment of the bone marrow niche, particularly a decrease in mesenchymal stromal cells (MSCs), is associated with cytopenia and graft failure after hematopoietic cell transplantation. Acute graft-versus-host disease (aGvHD) is shown to significantly reduce MSC numbers, and this reduction can be observed before clinical onset of aGvHD. The different phenotypic and functional characteristics of MSCs depending on the occurrence of aGvHD suggest that they may contribute to alloreactivity after transplantation.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Immunology

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?

Justin Loke, Richard Buka, Charles Craddock

Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Biophysics

Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty

Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Medicine, Research & Experimental

Graft conditioning with fluticasone propionate reduces graft-versus-host disease upon allogeneic hematopoietic cell transplantation in mice

Erika S. Varady, L. Angel Ayala, Pauline U. Nguyen, Vanessa M. Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A. Greilach, Craig M. Walsh, Matthew A. Inlay

Summary: Donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation increases HSC engraftment and reduces the severity and incidence of graft-versus-host disease (GvHD) in allogeneic hosts.

EMBO MOLECULAR MEDICINE (2023)

Add to Collection

Article Immunology

Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation

Yutong Tang, Zhenyang Zhou, Han Yan, Yong You

Summary: In this study, a case of AML patient with RUNX1-RUNX1T1 was reported, who underwent preemptive treatment with the combined application of tislelizumab and azacitidine to prevent post-transplant relapse. After the combination therapy, the patient achieved complete remission with improved hematologic response, but also experienced immune-related adverse events which were well controlled by immunosuppressive therapies.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Cell & Tissue Engineering

Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Rashin Mohseni, Pouya Mahdavi Sharif, Maryam Behfar, Mohammad Reza Modaresi, Rohola Shirzadi, Mahta Mardani, Leila Jafari, Fahimeh Jafari, Zeynab Nikfetrat, Amir Ali Hamidieh

Summary: This study aimed to assess the safety and effectiveness of adipose tissue-derived mesenchymal stem cells (AT-MSCs) for pediatric patients with bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The results showed that a single injection of AT-MSCs partially improved the symptoms of patients and the treatment was safe and tolerable.

STEM CELL RESEARCH & THERAPY (2023)

Add to Collection

Article Oncology

Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation

Hisashi Ishida, Motohiro Kato, Yuta Kawahara, Sae Ishimaru, Yuho Najima, Shinichi Kako, Maho Sato, Mitsuteru Hiwatari, Maiko Noguchi, Keisuke Kato, Katsuyoshi Koh, Keiko Okada, Fuminori Iwasaki, Ryoji Kobayashi, Shunji Igarashi, Shoji Saito, Yoshiyuki Takahashi, Atsushi Sato, Junji Tanaka, Yoshiko Hashii, Yoshiko Atsuta, Hirotoshi Sakaguchi, Toshihiko Imamura

Summary: This study retrospectively analyzed the outcomes of hematopoietic stem cell transplantation (HSCT) in children and adolescents with T-cell acute lymphoblastic leukemia (T-ALL). The results showed that HSCT at the first complete remission had better survival rates, but once relapse occurred, the prognosis was worse. Higher grades of graft versus host disease were associated with lower overall and leukemia free survival rates. Cord blood transplantation with total-body irradiation-based myeloablative conditioning showed better outcomes compared to other conditioning regimens.

HEMATOLOGICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Li Xuan, Qifa Liu

Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Immunology

Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation

Linlu Tian, Besim Ogretmen, Brian Y. Chung, Xue-Zhong Yu

Summary: Allogeneic hematopoietic cell transplantation is an effective immunotherapy against hematopoietic malignancies, but GVHD and tumor relapse are major concerns. Sphingolipid metabolism plays a crucial role in immune responses, highlighting the need to explore therapeutic strategies targeting sphingolipid metabolism.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

Yuexin Xu, Chris P. Miller, Edus H. Warren, Scott S. Tykodi

Summary: This review highlights the central role of T-cell immunity in the treatment of advanced RCC, providing an overview of clinical outcomes for antigen-targeted vaccines and other T-cell-engaging therapies. Emerging strategies to enhance the effectiveness of antigen-specific therapy for RCC are also discussed.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Article Genetics & Heredity

RNA helicase, DDX3X, is actively recruited to sites of DNA damage in live cells

Michael J. Cargill, Alicia Morales, Shashidhar Ravishankar, Edus H. Warren

Summary: Recent studies have shown that DDX3X accumulates at sites of DNA damage in the nucleus rapidly after induction, and its recruitment is mediated by its intrinsically disordered domains, similar to other RNA binding proteins. Inhibition of liquid-liquid phase separation also reduces DDX3X recruitment.

DNA REPAIR (2021)

Add to Collection

Letter Hematology

Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies

Chaitra Ujjani, Alexander L. Greninger, Mazyar Shadman, Joshua A. Hill, Ryan C. Lynch, Edus H. Warren, Ajay K. Gopal

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Review Pathology

Precision Medicine in Low- and Middle-Income Countries

Jerald P. Radich, Edward Briercheck, Daniel T. Chiu, Manoj P. Menon, Olga Sala Torra, Cecilia C. S. Yeung, Edus H. Warren

Summary: Most cancer cases occur in LMICs where the necessary infrastructure for optimal cancer care is lacking. However, examples of novel partnerships and creative solutions suggest that with determination, creativity, persistence, and some luck, precision medicine may be possible in these countries.

ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2022)

Add to Collection

Article Hematology

The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia

Chaitra Ujjani, Mazyar Shadman, Ryan C. Lynch, Brian Tu, Philip A. Stevenson, Caitlin Grainger, Haiying Zhu, Joshua A. Hill, Meei-Li Huang, Leslie Nielsen, Christina Poh, Tyler Sorensen, Ajay K. Gopal, Edus H. Warren, Brian G. Till, Sydney Lee, Daria Gausman, Stephen D. Smith, Ted Gooley, Alex Greninger

Summary: This study found that SARS-CoV-2 vaccine efficacy was lower in chronic lymphocytic leukemia (CLL) patients, with decreased rates of seroconversion and lower antibody levels compared to healthy controls. The results from the Roche anti-S assay and neutralization activity were similar. Durable immune responses were observed up to six months, and booster shots were effective in improving the immune response in patients who had a response. The absence of normal B cells, commonly seen in CLL patients receiving certain treatments, was a strong predictor of lack of seroconversion.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells

Charlotte A. James, Yuexin Xu, Melissa S. Aguilar, Lichen Jing, Erik D. Layton, Martine Gilleron, Adriaan J. Minnaard, Thomas J. Scriba, Cheryl L. Day, Edus H. Warren, David M. Koelle, Chetan Seshadri

Summary: This study reveals the importance of CD4 and CD8 co-receptors in recognizing mycobacterial glycolipid antigens. The expression of either CD4 or CD8 increases the avidity of T cell receptors for mycolipids, leading to a higher intensity of fluorescence and decreased secretion threshold for interferon-gamma. Furthermore, CD8+ T cells show greater cytotoxicity compared to CD4+ T cells in individuals with active tuberculosis.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Immunology

Serial Analysis of the T-Cell Receptor β-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy

Andrea M. H. Towlerton, Shashidhar Ravishankar, David G. Coffey, Camille E. Puronen, Edus H. Warren

Summary: Long-term antiretroviral therapy (ART) in people living with HIV (PLHIV) is associated with sustained increases in CD4(+) T-cell count, but its effect on the peripheral blood T-cell repertoire has not been comprehensively evaluated. In this study, serial profiling of the composition and diversity of the T-cell receptor beta-chain (TRB) repertoire before and after ART initiation in 30 adults with HIV infection revealed that ART increased the TRB repertoire diversity, but it remained lower than in the control group. The composition and structure of the TRB repertoires in PLHIV after long-term ART were also significantly perturbed compared to the control cohort.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

A prospective study of clinical outcomes of HIV-associated and HIV-negative Kaposi sarcoma in Uganda

Warren Phipps, Scott V. Adams, Peter Mooka, James Kafeero, Semei Sekitene, Dennis Mubiru, Janet Nankoma, Constance Namirembe, Lazarus Okoche, Elizabeth B. Namubiru, Shadiah Kayemba, Kelsey K. Baker, Mary W. Redman, Corey Casper, Jackson Orem, Edus H. Warren

Summary: This study aimed to understand the impact of HIV infection on Kaposi sarcoma (KS) patients and identify factors associated with survival and treatment response. Results showed low survival rates for both HIV-positive and HIV-negative KS patients, highlighting the need for new staging and therapeutic approaches.

AIDS (2023)

Add to Collection

Article Immunology

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer

David G. Coffey, Yuexin Xu, Andrea M. H. Towlerton, Marcin Kowanetz, Priti Hegde, Martine Darwish, Mahesh Yadav, Craig Blanchette, Shannon M. Ruppert, Sarah Bertino, Qikai Xu, Andrew Ferretti, Adam Weinheimer, Matthew Hellmann, Angel Qin, Dafydd Thomas, Edus H. Warren, Nithya Ramnath

Summary: This article reports the clinical history of an exceptional responder with metastatic non-small cell lung cancer who achieved a complete and enduring remission after treatment with radiation and atezolizumab, an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody. The study reveals oligoclonal T cell expansion and tumor reactivity in the patient, suggesting that the exceptional response may be attributed to increased tumor immunogenicity promoted by radiation therapy and the persistence of expanded T cell clones.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes

Yuexin Xu, Alicia J. Morales, Andrea M. H. Towlerton, Shreeram Akilesh, Chris P. Miller, Scott S. Tykodi, Edus H. Warren

Summary: This study provides insights into the characteristics of clonally expanded T cells in metastatic renal cell carcinoma (RCC), showing their higher density in tumors and their potential for effective immune therapy. The study also reveals different phenotypes of clonally expanded T cell subpopulations, which may play a significant role in immune therapy.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Anatomy & Morphology

Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma

Christopher P. Miller, Farinaz Shokri, Shreeram Akilesh, Yuexin Xu, Edus H. Warren, Scott S. Tykodi, Maria Tretiakova

Summary: 5T4 is a cancer/testis antigen highly expressed in renal cell carcinoma (RCC) and other cancers, but rarely in normal tissues. This study identified 3 monoclonal antibodies with 5T4 specificity and demonstrated high staining consistency in 263 renal tumors. These findings provide valuable reagents for detecting 5T4 in formalin-fixed, paraffin-embedded tissues and reveal heterogeneity in patient and histologic subtypes.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2023)

Add to Collection

Article Hematology

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Ryan C. Lynch, Christina Poh, Chaitra S. Ujjani, Edus H. Warren III, Stephen D. Smith, Mazyar Shadman, Karolyn Morris, Sydney Lee, Heather Rasmussen, Susan Ottemiller, Megan Shelby, Sarith Keo, Kaitlin Verni, David M. Kurtz, Ash A. Alizadeh, Jacob J. Chabon, Gregory J. Hogan, Andre Schulz, Ted Gooley, Jenna M. Voutsinas, Ajay K. Gopal

Summary: The POLARIX trial showed the superiority of Pola over vincristine in the RCHOP regimen for large B-cell lymphomas, but its safety in intensified regimens is unknown. This study evaluated the safety and efficacy of Pola-DA-EPCH-R in aggressive large B-cell lymphomas.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL

Solomon A. Graf, Ryan C. Lynch, Chaitra S. Ujjani, Ted A. Gooley, Heather Rasmussen, David G. Coffey, Andrew J. Cowan, Stephen D. Smith, Mazyar Shadman, Edus H. Warren, Edward N. Libby III, Alexander L. Greninger, Jonathan R. Fromm, Ajay K. Gopal

Summary: This study evaluated the efficacy of the oral proteasome inhibitor ixazomib as initial monotherapy and in combination with rituximab for the first-line treatment of iNHL. The results showed that both ixazomib monotherapy and combination therapy with rituximab demonstrated good efficacy in treating the disease, with manageable toxicities, convenience, and retention of the B-cell immune response.

BLOOD ADVANCES (2023)

Add to Collection

Article Multidisciplinary Sciences

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

David G. Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, J. Javier Diaz-Mejia, Ping Luo, Yong Zhang, Yuexin Xu, Edus H. Warren, Travis Dawson, Brian Lee, Hui Xie, Eric Smith, Amanda Ciardiello, Hearn J. Cho, Adeeb Rahman, Seunghee Kim-Schulze, Benjamin Diamond, Alexander Lesokhin, Dickran Kazandjian, Trevor J. Pugh, Damian J. Green, Sacha Gnjatic, Ola Landgren

Summary: This study investigates the role of the immune microenvironment in maintaining disease remission in patients with multiple myeloma. By analyzing the immune system composition before and after lenalidomide treatment, the researchers identify the correlation between the immune microenvironment and treatment response in newly diagnosed patients.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma

David G. Coffey, Andrew J. Cowan, Bret DeGraaff, Timothy J. Martins, Niall Curley, Damian J. Green, Edward N. Libby, Rebecca Silbermann, Sylvia Chien, Jin Dai, Alicia Morales, Ted A. Gooley, Edus H. Warren, Pamela S. Becker

Summary: In patients with relapsed or refractory MM, ex vivo drug sensitivity testing on isolated plasma cells from patient bone marrow biopsies or extramedullary plasmacytomas is feasible and may guide the next line of therapy.

JCO PRECISION ONCOLOGY (2021)

Add to Collection

No Data Available

Graft versus Leukemia Reactivity after Allogeneic Stem Cell Transplantation

Journal

Publisher

ELSEVIER SCIENCE INC

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper